One year after the world learned of He Jiankui’s editing of twins, gaps in rules remain.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
Cancer Cell International Open Access 15 September 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Opar, A. CRISPR-edited babies arrived, and regulators are still racing to catch up. Nat Med 25, 1634–1636 (2019). https://doi.org/10.1038/s41591-019-0641-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0641-x
This article is cited by
-
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
Cancer Cell International (2020)
-
CRISPR/Cas9 in Male Factor Infertility
Current Tissue Microenvironment Reports (2020)